Search Results
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
X
Youtube
Linkedin
September, 2024
September 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« Aug
Paolo Tarantino
Aug 15, 2023, 09:15 |
Insight
Paolo Tarantino: Delivering chemo via HER2- and Trop2-targeted Antibody-drug conjugates (ADCs) has reshaped the way we treat Metastatic breast cancer (MBC)
Paolo Tarantino, MD, Clinical Research Fellow at Dana-Farber Cancer Institute, stated on Twitter: "Delivering chemo…
Aug 6, 2023, 17:11 |
Blog
Here’s a personal, non-exhaustive selection of highly awaited phase 3 trials that may shape practice within the next year - Paolo Tarantino
With ESMO23 and SABCS23 approaching, we may soon see the results from several potentially practice-changing…
Jul 28, 2023, 08:26 |
Blog
Both T-DXd and SG are approved for patients with HER2-low TNBC. But which one has the strongest data in support? - Paolo Tarantino
Both T-DXd and SG are approved for patients with HER2-low TNBC. But which one has…
Jul 23, 2023, 16:19 |
Blog
The first oral SERD gets closer to Europe - Paolo Tarantino
Positive CHMP opinion on the marketing authorization of elacestrant for patients with HR+/HER2- MBC with…
Jul 19, 2023, 18:34 |
Insight
In breast oncology there is a pre-TDXd & a post-TDXd era, with the latter still at the dawn - Paolo Tarantino
In breast oncology there is a pre-TDXd & a post-TDXd era, with the latter still…
Jul 14, 2023, 07:05 |
Insight
Can an oral, alopecia-free treatment improve outcomes for MBC vs paclitaxel? - Paolo Tarantino
Can an oral, alopecia-free treatment improve outcomes for MBC vs paclitaxel? In METEORA2, just published…
Jul 9, 2023, 09:59 |
Insight
Phase 1 data from the auristatin HER2 ADC PF-06804103 highlight the importance of optimizing the toxicity profile of novel ADCs - Paolo Tarantino
Phase 1 data from the auristatin HER2 ADC PF-06804103 highlight the importance of optimizing the…
Jul 5, 2023, 05:17 |
Blog
The formatted version of the ESMO Consensus Statements on HER2-low breast cancer is finally published - Paolo Tarantino
The formatted version of the ESMO Consensus Statements on HER2-low breast cancer is finally published…
Jun 28, 2023, 17:38 |
Positive
ADCs keep showing impressive activity across cancers - Paolo Tarantino
ADCs keep showing impressive activity across cancers. 1L EV+pembro led to 64% ORR among patients…
Jun 10, 2023, 02:53 |
Blog
Patients progressing on 1L palbo should not receive further exposure to palbo- Paolo Tarantino
Consistent with the PACE trial, the PALMIRA randomized phase 2 trial showed no benefit in…
13
14
15
16
17
All:
196
Posts:
141 - 150
Paolo Tarantino: Top 10 Breast Cancer abstracts from ESMO2024
100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 2
Running for a Cure: The Legacy of Terry Fox's Marathon of Hope
How The Breast Cancer Research Foundation was founded
Can Skin Cancer be Prevented by a $0.50 Soap? Meet TIME’s Kid of the Year and His Invention
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube